Expression and Clinical Significance of miRNA-34a in Colorectal Cancer

  • Ma, Zhi-Bin (Department of Gastroenterology, the First Affiliated Hospital of Harbin Medical University) ;
  • Kong, Xiao-Lin (Department of Hematology, the First Affiliated Hospital of Harbin Medical University) ;
  • Cui, Gang (Department of Hematology, the First Affiliated Hospital of Harbin Medical University) ;
  • Ren, Cui-Cui (Department of Hematology, the First Affiliated Hospital of Harbin Medical University) ;
  • Zhang, Ying-Jie (Department of Hematology, the First Affiliated Hospital of Harbin Medical University) ;
  • Fan, Sheng-Jin (Department of Hematology, the First Affiliated Hospital of Harbin Medical University) ;
  • Li, Ying-Hua (Department of Hematology, the First Affiliated Hospital of Harbin Medical University)
  • Published : 2014.11.28


Background: The aim of this study was to investigate differences of miRNA-34a expression in benign and malignant colorectal lesions. Materials and Methods: Samples of cancer, paraneoplastic tissues and polyps were selected and total RNA was extracted by conventional methods for real-time PCR to detect the miRNA-34a expression. In addition, the LOVO colorectal cancer cell line was cultured, treated with the demethylating agent 5-azacytidine and screened for differentially expressed miRNA-34a. Results: After the drug treatment, the miRNA-34a expression of colorectal cancer cell line LOVO was increased and real-time PCR showed that levels of expression in both cell line and colorectal cancer tissues were low, as compared to paraneoplastic tissue (p<0.05). Polyps tissues had significantly higher expression than paraneoplastic and colorectal cancer samples (p<0.05). Conclusions: miRNA-34a-5p may play a role as a tumor suppressor gene in colorectal cancer, with involvement of DNA methylation.


Supported by : Department of Education in Heilongjiang Province


  1. Aranha MM, Santos DM, Sola S, Steer CJ, Rodrigues CM (2011). miR-34a regulates mouse neural stem cell differentiation. PloS One, 6, 21396.
  2. Bao N, Lye KW, Barton MK (2004). MicroRNA binding sites in Arabidopsis class III HD-ZIP mRNAs are required for methylation of the template chromosome. Dev Cell, 7, 653-62.
  3. Bartel DP (2009). MicroRNAs: Target recognition and regulatory functions. Cell, 136, 215-33.
  4. Calin GA, Sevignani C, Dumitru CD, et al (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA, 101, 2999-3004.
  5. Chang TC, Wentzel EA, Kent OA, et al (2007). Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell, 26, 745-52.
  6. Corte H, Manceau G, Blons H, et al (2012). MicroRNA and colorectal cancer. Dig Liver Dis, 44, 195-200.
  7. Giraldez MD, Lozano JJ, Ramirez G, et al (2013). Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study. Clin Gastroenterol Hepatol, 11, 681-8.
  8. Grady WM, Parkin RK, Mitchell PS, et al (2008). Epigenetic silencing of the intronic microRNA has-miR-342 and its host gene EVL in colorectal cancer. Oncogene, 27, 3880-8.
  9. Guessous F, Zhang Y, Kofman A, et al (2010). miRNA-34a-5p is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle, 9, 1031-6.
  10. He L, He X, Lim LP, et al (2007a). A microRNA component of the p53 tumour suppressor network. Nature, 447, 1130-4.
  11. He L, He X, Lowe SW, Hannon GJ (2007b). MicroRNAs join the p53 network-another piece in the tumour suppression puzzle. Nat Rev Cancer, 7, 819-22.
  12. He X, He L, Hannon GJ (2007c). The guardian's little helper: Micro-RNAs in the p53 tumor suppressor network. Cancer Res, 67, 11099-101.
  13. Hermeking H (2010). The miR-34 family in cancer and apoptosis. Cell Death Differ, 17, 193-9.
  14. Kanaan Z, Rai SN, Eichenberger MR, et al (2012). Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg, 256, 544-51.
  15. Kim HC, Lee HJ, Roh SA, et al (2008). CpG island methylation in familial colorectal cancer patients not fulf illing the Amsterdam criteria. J Korean Med Sci, 23, 270-7.
  16. Kumar K, Brim H, Giardiello F, et al (2009). Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans. Clin Cancer Res, 15, 1155-61.
  17. Liu C, Kelnar RK, Liu B, et al (2011). The microRNA miR34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med, 17, 211-5.
  18. Raver-Shapira N, Marciano E, Meiri E, et al (2007). Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell, 26, 731-43.
  19. Schimanski CC, Frerichs K, Rahman F, et al (2009). High miR-196a levels promote the Oncogenic phenotype of colorectal cancer cells. World J Gastroenterol, 15, 2089-96.
  20. Tarasov V, Jung P, Verdoodt B, et al (2007). Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle, 6, 1586-93.
  21. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H (2007). Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci USA, 104, 15472-7.
  22. Toyota M, Suguki H, Sasaki Y, et al (2008). Epigenetic silencing of microRNA-34b/c and B-cell translocation gene4 is associated with CpG island methylation in colorectal cancer. Cancer Res, 68, 4123-32.
  23. Vilkin A, Niv Y, Nagasaka T, et al (2009). Microsatellite in stability, MLH 1 promoter methylation, and BRAF mutat ion analys is in sporad ic colorectal cancers of d ifferent ethn ic groups in Israel. Cancer, 115, 760-9.
  24. Vinall RL, Ripoll AZ, Wang S, Pan CX, deVere White RW (2012). MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of P53-Rb pathway status. Int J Cancer, 130, 2526-38.
  25. Vire E, Brenner C, Deplus R, et al (2006) The Polycomb group protein EZH 2 directly controls DNA methylation. Nature, 439, 871-4.
  26. Weber B, Stresemann C, Brueckner B, Lyko F (2007). Methylation of human microRNA genes in normal and neolastic cells. Cell Cycle, 6, 1001-5.
  27. Welch C, Chen Y, Stallings RL (2007). MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene, 26, 5017-22.
  28. Wu CW, Ng SS, Dong YJ, et al (2012). Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut, 61, 739-45.
  29. Yamakuchi M, Lowenstein CJ (2009). MiR-34, SIRT1 and P53: the feedback loop. Cell Cycle, 8, 712-5.
  30. Zanette DL, Rivadavia F, Molfetta GA, et al (2007). miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia. Braz J Med Biol Res, 40, 1435-40.
  31. Zhou T, Zhang G, Liu Z, et al (2013). Overexpression of miR-92a correlates with tumor metastasis and poor prognosis in patients with colorectal cancer. Int J Colorectal Dis, 28, 19-24.
  32. Zhou XJ, Dong ZG, Yang YM, et al (2013). Limited diagnostic value of microRNAs for detecting colorectal cancer: A Meta-analysis. Asian Pac J Cancer Prev, 14, 4699-704.

Cited by

  1. microRNA Expression Profile in Patients with Stage II Colorectal Cancer: A Turkish Referral Center Study vol.16, pp.5, 2015,
  2. miRNA-34a-5p downregulation of VEGFA in endometrial stem cells contributes to the pathogenesis of endometriosis vol.16, pp.6, 2017,